Freestone Grove Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Freestone Grove Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$34.2M	Buy	606,187 +114,285	+23%	+$6.66M	0.24%	143
2025 Q4	$29.2M	Buy	491,902 +15,466	+3%	+$842K	0.21%	158
2025 Q3	$25.8M	Buy	476,436 +140,923	+42%	+$8.06M	0.19%	175
2025 Q2	$18.4M	Buy	+335,513	New	+$19.8M	0.14%	208

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Freestone Grove Partners's BMRN Position: Q1 2026 in Review

Freestone Grove Partners increased its BioMarin Pharmaceuticals (BMRN) stake by 23% in Q1 2026, buying an estimated $6.66M and bringing the position to 606,187 shares worth $34.2M. The position accounts for 0.24% of the portfolio, ranked #143.

Freestone Grove Partners first reported a position in BMRN in Q2 2025 and has held it in 4 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Freestone Grove Partners held 606,187 shares of BioMarin Pharmaceuticals worth $34.2M as of Q1 2026.
Freestone Grove Partners bought 114,285 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $6.66M.
BioMarin Pharmaceuticals made up 0.24% of Freestone Grove Partners's portfolio in Q1 2026, its #143 holding.
Freestone Grove Partners first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.